Richard Moore Cawthon
Physician in Salt Lake City, UT
License number
Utah 178996-8905
Issued Date
Jul 20, 1988
Expiration Date
Jan 31, 2006
Category
Physician
Type
Physician/Surgeon CS (Schedule 2-5)
Address
Address
Salt Lake City, UT
Personal information
See more information about Richard Moore Cawthon at radaris.comName
Address
Phone
1023 S 800 E, Salt Lake City, UT 84105
586 E E St, Salt Lake Cty, UT 84103
586 E E St, Salt Lake City, UT 84103
586 St, Salt Lake City, UT 84103
785 10Th Ave, Salt Lake City, UT 84103
Professional information
See more information about Richard Moore Cawthon at trustoria.com
Reducing Non-Target Nucleic Acid Dependent Amplifications: Amplifying Repetitive Nucleic Acid Sequences
Reducing Non-Target Nucleic Acid Dependent Amplifications: Amplifying Repetitive Nucleic Acid Sequences
US Patent:
8048631, Nov 1, 2011
Filed:
Feb 4, 2010
Appl. No.:
12/700475
Inventors:
Richard Cawthon - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/04
US Classification:
435 612, 435 922, 536 2433
Abstract:
The present invention provides for compositions and methods for amplifying target nucleic acids using nucleic acid primers designed to limit non-target nucleic acid dependent priming events. The present invention permits amplifying and quantitating the number of repetitive units in a repetitive region, such as the number of telomere repetitive units.
Reducing Non-Target Nucleic Acid Dependent Amplifications: Amplifying Repetitive Nucleic Acid Sequences
Reducing Non-Target Nucleic Acid Dependent Amplifications: Amplifying Repetitive Nucleic Acid Sequences
US Patent:
7695904, Apr 13, 2010
Filed:
Jan 31, 2003
Appl. No.:
10/355626
Inventors:
Richard M Cawthon - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salk Lake City UT
International Classification:
C12Q 1/68
US Classification:
435 6, 435 911, 435 912
Abstract:
The present invention provides for compositions and methods for amplifying target nucleic acids using nucleic acid primers designed to limit non-target nucleic acid dependent priming events. The present invention permits amplifying and quantitating the number of repetitive units in a repetitive region, such as the number of telomere repetitive units.
Somatic Mutations In Neurofibromatosis Type 1 Gene In Human Tumors
Somatic Mutations In Neurofibromatosis Type 1 Gene In Human Tumors
US Patent:
5605799, Feb 25, 1997
Filed:
Mar 28, 1995
Appl. No.:
8/411389
Inventors:
Raymond L. White - Salt Lake City UT
Richard M. Cawthon - Salt Lake City UT
Ying Li - Salt Lake City UT
Richard M. Cawthon - Salt Lake City UT
Ying Li - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 168, C12P 1934, C07H 2104, C12N 1500
US Classification:
435 6
Abstract:
The present invention is directed to somatic mutations of the NF1 gene which are found in human tumors. In addition, the present invention is directed to methods of screening humans to determine those having somatic mutations in the NF1 gene in tumors. Finally, the invention is directed to a method of treating a human having a tumor with a somatic mutation in the NF1 gene by restoring natural regulation of ras proteins.
Monochrome Multiplex Quantitative Pcr
Monochrome Multiplex Quantitative Pcr
US Patent:
2011029, Dec 1, 2011
Filed:
Dec 22, 2009
Appl. No.:
13/141429
Inventors:
Richard M. Cawthon - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH FOUNDATION - Salt Lake City UT
International Classification:
C40B 30/00
US Classification:
506 7
Abstract:
Disclosed herein are methods and compositions for determining the copy number of a first target nucleic acid as compared to the copy number of a second target nucleic acid in a single well with a single detection label. For example, disclosed herein are methods and compositions for determining the copy number of a first target nucleic acid as compared to the copy number of a second target nucleic acid by a monochrome multiplex quantitative PCR (MMQPCR) in a single well with a single detection label.
Methods And Kits For Determining Biological Age And Longevity Based On Gene Expression Profiles
Methods And Kits For Determining Biological Age And Longevity Based On Gene Expression Profiles
US Patent:
2011020, Aug 25, 2011
Filed:
Feb 16, 2011
Appl. No.:
13/028910
Inventors:
Richard M. Cawthon - Salt Lake City UT, US
Richard A. Kerber - Louisville KY, US
Sandra J. Hasstedt - Salt Lake City UT, US
Elizabeth O'Brien - Louisville KY, US
Richard A. Kerber - Louisville KY, US
Sandra J. Hasstedt - Salt Lake City UT, US
Elizabeth O'Brien - Louisville KY, US
International Classification:
C12Q 1/68
US Classification:
435 611, 435 618, 435 61
Abstract:
Described herein are methods of predicting the likelihood of survival in a subject. Additionally, described herein are methods of modulating survival in a subject.
Methods Of Predicting Mortality Risk By Determining Telomere Length
Methods Of Predicting Mortality Risk By Determining Telomere Length
US Patent:
2006021, Sep 21, 2006
Filed:
Jan 26, 2004
Appl. No.:
10/543111
Inventors:
Richard Cawthon - Salt Lake City UT, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention provides for methods of determining telomere length of an organism and correlating the measured telomere length with mortality risk associated with telomere length in a population. The presence of shorter telomeres is associated with an increased mortality rate and increased susceptibility to certain types of diseases for an individual member of a human population.
Neurofibromatosis Type 1 Gene
Neurofibromatosis Type 1 Gene
US Patent:
5227292, Jul 13, 1993
Filed:
Jul 12, 1990
Appl. No.:
7/551531
Inventors:
Raymond L. White - Salt Lake City UT
Peter O'Connell - Midvale UT
David H. Viskochil - Salt Lake City UT
Richard M. Cawthon - Salt Lake City UT
Peter O'Connell - Midvale UT
David H. Viskochil - Salt Lake City UT
Richard M. Cawthon - Salt Lake City UT
Assignee:
University of Utah - Salt Lake City UT
International Classification:
C12Q 168, C12P 2106, C12N 1500, C07H 1512
US Classification:
435 691
Abstract:
The present invention relates to the neurofibromatosis type 1 (NF1) gene and its gene product. The invention further relates to methods for the detection in and treatment of humans having defective NF1 genes and for detection of tumors caused by a defective NF1 gene.